A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents.
Clinical trial
Elderly
Myeloid diseases
Protein neddylation
Therapy
Journal
Journal of hematology & oncology
ISSN: 1756-8722
Titre abrégé: J Hematol Oncol
Pays: England
ID NLM: 101468937
Informations de publication
Date de publication:
08 Jul 2023
08 Jul 2023
Historique:
received:
26
05
2023
accepted:
04
07
2023
medline:
10
7
2023
pubmed:
9
7
2023
entrez:
8
7
2023
Statut:
epublish
Résumé
Pevonedistat is a first-in-class, small molecular inhibitor of NEDD8-activating enzyme that has clinical activity in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Preclinical data suggest synergy of pevonedistat with azacitidine and venetoclax. This single-center, phase 1/2 study evaluated the combination of azacitidine, venetoclax and pevonedistat in older adults with newly diagnosed secondary AML or with MDS or chronic myelomonocytic leukemia (CMML) after failure of hypomethylating agents. Patients received azacitidine 75 mg/m Forty patients were enrolled (32 with AML and 8 with MDS/CMML). In the AML cohort, the median age was 74 years (range 61-86 years), and 27 patients (84%) had at least one adverse risk cyto-molecular feature, including 15 (47%) with a TP53 mutation or MECOM rearrangement; seventeen patients (53%) had received prior therapy for a preceding myeloid disorder. The CR/CRi rate was 66% (CR 50%; CRi 16%), and the median overall survival (OS) was 8.1 months. In the MDS/CMML cohort, 7 patients (87%) were high or very high risk by the IPSS-R. The overall response rate was 75% (CR 13%; mCR with or without HI 50%; HI 13%). The most common grade 3-4 adverse events were infection in 16 patients (35%), febrile neutropenia in 10 patients (25%) and hypophosphatemia in 9 patients (23%). In an exploratory analysis, early upregulation of NOXA expression was observed, with subsequent decrease in MCL-1 and FLIP, findings consistent with preclinical mechanistic studies of pevonedistat. Upregulation of CD36 was observed, which may have contributed to therapeutic resistance. The triplet combination of azacitidine, venetoclax and pevonedistat shows encouraging activity in this very poor-risk population of patients with AML, MDS or CMML. Trial registration ClinicalTrials.gov (NCT03862157).
Sections du résumé
BACKGROUND
BACKGROUND
Pevonedistat is a first-in-class, small molecular inhibitor of NEDD8-activating enzyme that has clinical activity in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Preclinical data suggest synergy of pevonedistat with azacitidine and venetoclax.
METHODS
METHODS
This single-center, phase 1/2 study evaluated the combination of azacitidine, venetoclax and pevonedistat in older adults with newly diagnosed secondary AML or with MDS or chronic myelomonocytic leukemia (CMML) after failure of hypomethylating agents. Patients received azacitidine 75 mg/m
FINDINGS
RESULTS
Forty patients were enrolled (32 with AML and 8 with MDS/CMML). In the AML cohort, the median age was 74 years (range 61-86 years), and 27 patients (84%) had at least one adverse risk cyto-molecular feature, including 15 (47%) with a TP53 mutation or MECOM rearrangement; seventeen patients (53%) had received prior therapy for a preceding myeloid disorder. The CR/CRi rate was 66% (CR 50%; CRi 16%), and the median overall survival (OS) was 8.1 months. In the MDS/CMML cohort, 7 patients (87%) were high or very high risk by the IPSS-R. The overall response rate was 75% (CR 13%; mCR with or without HI 50%; HI 13%). The most common grade 3-4 adverse events were infection in 16 patients (35%), febrile neutropenia in 10 patients (25%) and hypophosphatemia in 9 patients (23%). In an exploratory analysis, early upregulation of NOXA expression was observed, with subsequent decrease in MCL-1 and FLIP, findings consistent with preclinical mechanistic studies of pevonedistat. Upregulation of CD36 was observed, which may have contributed to therapeutic resistance.
CONCLUSIONS
CONCLUSIONS
The triplet combination of azacitidine, venetoclax and pevonedistat shows encouraging activity in this very poor-risk population of patients with AML, MDS or CMML. Trial registration ClinicalTrials.gov (NCT03862157).
Identifiants
pubmed: 37422688
doi: 10.1186/s13045-023-01476-8
pii: 10.1186/s13045-023-01476-8
pmc: PMC10329789
doi:
Substances chimiques
Azacitidine
M801H13NRU
venetoclax
N54AIC43PW
pevonedistat
S3AZD8D215
Banques de données
ClinicalTrials.gov
['NCT03862157']
Types de publication
Clinical Trial, Phase II
Clinical Trial, Phase I
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
73Informations de copyright
© 2023. The Author(s).
Références
Blood. 2015 Feb 26;125(9):1367-76
pubmed: 25550361
Leuk Lymphoma. 2017 Sep;58(9):1-17
pubmed: 28140720
Blood Adv. 2017 Jul 19;1(17):1312-1323
pubmed: 29296774
Lancet Haematol. 2019 Jan;6(1):e29-e37
pubmed: 30545576
J Clin Oncol. 2015 Apr 10;33(11):1252-7
pubmed: 25732165
Blood. 2006 Jul 15;108(2):419-25
pubmed: 16609072
Blood. 2017 Jan 26;129(4):424-447
pubmed: 27895058
Sci Rep. 2021 Jun 11;11(1):12388
pubmed: 34117319
N Engl J Med. 2020 Aug 13;383(7):617-629
pubmed: 32786187
Cell Death Differ. 2015 Dec;22(12):2133-42
pubmed: 26045051
Haematologica. 2014 Mar;99(3):465-73
pubmed: 24142997
Blood Adv. 2020 Jul 14;4(13):2866-2870
pubmed: 32589727
Cell Stem Cell. 2016 Jul 7;19(1):23-37
pubmed: 27374788
Blood. 2015 Mar 19;125(12):1857-65
pubmed: 25624319
Cancer. 2016 Dec 15;122(24):3821-3830
pubmed: 27529519
Cancer. 2016 Nov 15;122(22):3484-3491
pubmed: 27463065
Haematologica. 2023 Mar 23;:
pubmed: 36951163
N Engl J Med. 2018 Oct 11;379(15):1443-1451
pubmed: 30304652
Br J Haematol. 2015 May;169(4):534-43
pubmed: 25733005
Blood Rev. 2017 Mar;31(2):43-62
pubmed: 27745715
Nature. 2009 Apr 9;458(7239):732-6
pubmed: 19360080
Haematologica. 2022 Apr 01;107(4):825-835
pubmed: 33853293
J Clin Oncol. 2015 Nov 1;33(31):3641-9
pubmed: 26304885
Blood Adv. 2022 Sep 13;6(17):5132-5145
pubmed: 35728048
Clin Trials. 2005;2(6):467-78
pubmed: 16422307
Am J Hematol. 2023 Feb;98(2):272-281
pubmed: 36309981
Blood. 2018 Mar 29;131(13):1415-1424
pubmed: 29348128
Leukemia. 2021 Jul;35(7):2119-2124
pubmed: 33483617
Blood. 2016 May 19;127(20):2391-405
pubmed: 27069254
Stat Med. 1995 Feb 28;14(4):357-79
pubmed: 7746977
Cancer. 2017 Feb 1;123(3):426-435
pubmed: 27657543
Nat Cancer. 2020 Dec;1(12):1176-1187
pubmed: 33884374
Blood. 2010 May 6;115(18):3796-800
pubmed: 20203261
Clin Cancer Res. 2009 Jun 15;15(12):3912-6
pubmed: 19509147
Cancer. 2021 Oct 15;127(20):3772-3781
pubmed: 34255353
J Hematol Oncol. 2022 Jan 29;15(1):12
pubmed: 35093134
J Clin Oncol. 2011 Aug 20;29(24):3322-7
pubmed: 21788559
Cancer. 2010 Aug 15;116(16):3830-4
pubmed: 20564137
Blood Adv. 2023 Jun 13;7(11):2360-2363
pubmed: 36315007